Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03003104 · ClinicalTrials.gov registry record · Phase 2
DMT210 Topical Gel in the Treatment of Acne Rosacea
A Phase 2 study, sponsored by Dermata Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 107
- Enrollment target
NCT03003104 is a Phase 2 study that has completed, run by Dermata Therapeutics. The registered enrollment target is 107 participants.
The verdict
NCT03003104, a Phase 2 study, has completed, sponsored by Dermata Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 107 participants
- Enrollment target
Study Summary
The study evaluates the safety, tolerability, and efficacy of DMT210 Gel, 5% when applied twice daily for 12 weeks in adult patients with moderate to severe acne rosacea. Half of participants will receive DMT210 Gel while the other half will receive vehicle control.
Interventions
- OTHER Vehicle Control
- DRUG DMT210 Topical Gel 5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2017-01 |
| Est. Completion | 2017-08-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03003104
The ClinicalTrials.gov registry entry for NCT03003104 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dermata Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Control is the first listed.
NCT03003104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03003104 about?
NCT03003104 is a clinical study titled "DMT210 Topical Gel in the Treatment of Acne Rosacea". The study evaluates the safety, tolerability, and efficacy of DMT210 Gel, 5% when applied twice daily for 12 weeks in adult patients with moderate to severe acne rosacea. Half of participants will receive DMT210 Gel while the other half will receive vehicle control.
What is the current status of trial NCT03003104?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2017-01. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT03003104?
The interventions under investigation include: Vehicle Control (OTHER), DMT210 Topical Gel 5% (DRUG).
Who is sponsoring clinical trial NCT03003104?
This trial is sponsored by Dermata Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.